𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents

✍ Scribed by Alan W Partin; Leonard S Marks

Book ID
117263371
Publisher
Elsevier Science
Year
2001
Tongue
English
Weight
252 KB
Volume
57
Category
Article
ISSN
0090-4295

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Evaluation of serum prostate-specific an
Evaluation of serum prostate-specific antigen in urologic cancers
✍ Toshimi Takeuchi; Manabu Kuriyama; Shigeru Fujihiro; Yoshinori Fujimoto; Manabu πŸ“‚ Article πŸ“… 1983 πŸ› John Wiley and Sons 🌐 English βš– 288 KB

## Abstract Serum prostate‐specific antigen (PA), a new tumor marker of prostate cancer, was evaluated with an enzyme immunoassay (EIA) in various urologic cancer patients and benign prostatic diseases in Japanese. Sera of prostate cancer patients before treatment (n = 27) revealed a range of PA co

Evaluation and comparison of two new pro
Evaluation and comparison of two new prostate carcinoma markers: Free-prostate specific antigen and prostate specific membrane antigen
✍ Gerald P. Murphy; Robert J. Barren; Sheila J. Erickson; Victoria A. Bowes; Rober πŸ“‚ Article πŸ“… 1996 πŸ› John Wiley and Sons 🌐 English βš– 816 KB

## BACKGROUND. Two new prostate cancer markers, free-prostate specific antigen (f-PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two-year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.

Prostate-specific antigen: A surrogate e
Prostate-specific antigen: A surrogate endpoint for screening new agents against prostate cancer?
✍ SchrοΏ½der, Fritz H.; Kranse, Ries; Barbet, Nik; Hop, Wim C.J.; Kandra, Albert; La πŸ“‚ Article πŸ“… 2000 πŸ› John Wiley and Sons 🌐 English βš– 206 KB πŸ‘ 2 views

BACKGROUND. An endpoint for clinical trials of prostate cancer which simplifies traditional endpoints (response of measurable lesions, progression rates, and death) is urgently needed. This is especially true for hormone-unresponsive disease, for which many new drugs are presently in a development p